|
As we move into the new year, we are reaching the midpoint of the RSV season. This is a critical time to review inventory, plan administration for the remainder of the season, and coordinate use of all available doses. RSV product administration ends March 31 - we are now halfway through the administration season.
After reviewing administration and inventory data, here is our current status:
Doses administered from January 2025 - March 2025 (end of 2024-2025 season):
- 5,000 doses of 50 mg product
- 1,700 doses of 100 mg product
Current inventory in facilities as of January 5, 2025:
- 4,880 doses of 50 mg product - almost equivalent to what was used last year
- 4,250 doses of 100 mg product - 2.5 times more doses in inventory than what was administered last year
- 3,490 of these doses will expire before the start of next season
We need your continued collaboration to get these doses administered by the end of the season. Using available inventory now helps minimize waste and make doses available to order earlier next season.
RSV Action Needed
- All doses expiring before September 30, 2026, must be administered by March 31. Fewer than 90 days remain in the season.
- Providers should have a clear plan to use all RSV product by March 31.
- Review on-hand inventory and make a plan to immunize patients.
- Advertise doses immediately in the IIS if product will not be used in 90 days.
We will be reaching out to providers with inventory to offer support with dose transfers. Please be prepared to share your plan to use available doses. Providers may be asked to accept a transfer before new orders are approved.
Key reminders:
- Nonexpired RSV doses cannot be returned at the end of the season.
- Ordering for the new RSV monoclonal antibody product clesrovimab (ENFLONSIA) opened January 2, 2026.
- Providers must choose one RSV product for infants under 8 months of age: either clesrovimab (ENFLONSIA) or nirsevimab (Beyfortus).
- Providers are not required to order clesrovimab and may continue to order nirsevimab.
- Orders for clesrovimab will not be approved until the ordering facility is at a 2-week supply of nirsevimab.
- Adding a new RSV product requires advance planning. Providers considering a transition to clesrovimab should complete all planning steps before placing order.
Regardless of which RSV product is selected, we encourage providers to work together to redistribute existing RSV doses across the state. Our shared goal is to end the season with little to no remaining inventory, protecting Washington's children while minimizing waste.
Resources for Providers
The following resources are available to support RSV product decision-making and planning:
|
